INBX: director bought $567,580 of Inhibrx Biosciences, Inc.
The filing shows 1 Table I transaction by a director of Inhibrx Biosciences, Inc.: bought $567,580. Source document and our reading of it are below; the SEC filing is the record, this page is the index.
Freshness
UTC: accepted 2026-09-08T21:23:30Z · seen 2026-09-08T22:00:57Z. Measured per filing; the distribution for every day is on coverage.
What the filing shows (Table I)
| Trade date | Code | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|
| Sep 08, 2026 | P · Open-market or private purchase | 5,000 | $113.52 | $567,580 | 424,360 |
- Reporting person
- Kayyem Jon Faiz · Director
- Issuer
- Inhibrx Biosciences, Inc. · CIK 2007919
- Accession
- 0001366268-26-000004
- Source
- SEC filing index · complete submission
- Rule 10b5-1
- checkbox not captured by our parser yet — check the filing
Checks
filing price is 0.99× the 2026-09-08 close (close $114.34 on 2026-09-08). Band: filing price within 0.4–2.5× of the last market close on or before the trade date; a filing outside the band is not published. Rows dropped by our data checks (duplicates, superseded amendments, impossible values, bulk program events, price outside the band) are excluded from every number on this page.
INBX insider flow — 30 days to this filing
Definition: 3 or more distinct insiders reported open-market purchases within a 10-trading-day window, and the net open-market flow over the whole period shown is positive. The label is data, not a judgement.
| Filed | Reporting person | Codes | Rows | Buys | Sells | Filing |
|---|---|---|---|---|---|---|
| Sep 08, 2026 | FORSYTH DOUGLAS · Director | P | 1 | $286,617 | — | 0001240801-26-000004 |
| Sep 08, 2026 | Lappe Mark · Chief Executive Officer | P | 6 | $2,645,399 | — | 0001366074-26-000002 |
| Sep 08, 2026 | Kayyem Jon Faiz · Director | P | 1 | $567,580 | — | 0001366268-26-000004 (this filing) |
Reading
The most ordinary reading of several insiders buying in the same window is directors and officers adding to holdings in an open trading window, often after results are public. Form 4 does not state a reason, and this page does not infer one.
Scope: SEC Form 4, Table I (non-derivative) only — Table II (options, RSUs) is not shown; on multi-owner filings the first reporting owner; Senate PTRs are covered, House is not. Every filing is reconciled daily against EDGAR's own index — see coverage.
Generated 2026-09-08 22:04 UTC from our reconciled ledger. Amended filings (Form 4/A) replace this page with a notice, they do not delete it. Found an error? [email protected].